The axial spondyloarthritis (AxSpA) market boasts biologics representing two distinct drug classes, the blockbuster tumor necrosis factor-alpha (TNF-α) inhibitors (Amgen’s Enbrel, AbbVie’s Humira, Janssen’s Remicade and Simponi / Simponi Aria, and UCB’s Cimzia) and one IL-17 inhibitor (Novartis’s Cosentyx). The TNF-α inhibitors are the most widely prescribed biologics in AxSpA patients refractory to nonsteroidal anti-inflammatory drugs (NSAIDs). However, these agents face a competitive threat, both from the launch of cost-effective biosimilars and the growing IL-17 class, which has efficacy data that have met more-stringent clinical trial endpoints. Cimzia was approved by the FDA in March 2019 for nonradiographic (nr)-AxSpA, marking the first FDA approval for that subpopulation. The impending entry of additional IL-17 inhibitors (Eli Lilly’s Taltz, UCB’s bimekizumab, and Kyowa Hakko Kirin’s Lumicef) and the first oral targeted therapy for this indication (Pfizer’s Jak inhibitor Xeljanz) will also shift market dynamics.
Questions answered:
Content highlights:
Geographies: United States, EU5, Japan
Primary Research: ~30 country-specific interviews with thought-leading rheumatologists; Supported by survey data collected for this and other DRG research
Epidemiology: Diagnosed prevalent cases of axial spondyloarthritis by country, ankylosing spondylitis and nonradiographic axial spondyloarthritis subpopulations
Forecast: 10-year, annualized, drug-level sales and patient share of key axial spondyloarthritis therapies through 2028, segmented by brands/generics and epidemiological subpopulations
Emerging therapies: Phase III/PR: 4 drugs; Phase II: 2 drugs
Product description:
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.